The remede® System is an implantable device in development by Respicardia, Inc. which is designed to restore a more normal breathing pattern during sleep in people with central sleep apnoea.
Nintedanib is already licensed for treating idiopathic pulmonary fibrosis which is a subtype of ILDs. Nintedanib acts by blocking specific enzymes and pathways that lead to the development of blood vessels within lung cells involved in the scarring process. This inhibits further growth of the scarring tissues resulting in slowing of the disease progression. This action has been shown to be similar in patients with idiopathic pulmonary fibrosis. If licensed, nintedanib may provide the first novel therapy for PF-ILD where limited treatment options currently exist.